Prev
The inaugural CHIPS 2026 China-Global Healthcare Investment & Partnership Summit was successfully held from October 29 to 31. As a key participant, Jumbo Sheen Fund attended the event in its capacity as an investment institution while taking on a special role. Hosted by IQVIA, the conference saw Quintiles Fund as a supporting co-organiser. As the fund manager of Quintiles Fund — IQVIA’s first onshore fund in China — our team took part in the conference in full depth. Leveraging this exclusive cooperation platform, we engaged in multi-layered exchanges with global healthcare industry partners, innovative enterprises and fellow investors.
IQVIA (NYSE: IQV) is a world-leading integrated information and technology-enabled healthcare services provider, formed via the merger of two industry giants, Quintiles and IMS Health. Its business spans more than 100 countries and regions worldwide. It has long served global multinational pharmaceutical companies and maintains deep connections with numerous Chinese innovative drug and device firms, widely recognised as an industry benchmark for data, technology and professional services. Drawing on this global vision and industrial network, IQVIA co-hosted CHIPS 2026 together with CICC Capital and the China-Portugal Economic and Trade Centre, bringing global buyers, capital pools and innovative projects together at a unified transaction platform.
At the conference, the Jumbo Sheen Fund team attended the keynote sessions and held in-depth discussions with industry partners and peer investors. The team exchanged views on hot topics including the commercialisation pathways of innovative drug and device pipelines, investment logic for medical hard tech, cross-border pharmaceutical collaboration opportunities, and evolving industrial policies, while actively sourcing high-quality projects with technological moats, clinical value and globalisation potential.
Life sciences and healthcare represent one of the core hard-tech sectors that Jumbo Sheen Fund focuses on over the long term. Anchored in industrial value, we continue to deepen our footprint in biopharmaceuticals, high-end medical devices and life science technologies. Drawing on our industrial resources and investment expertise, we support the growth of promising innovators and help translate domestic medical innovation achievements into broader global markets.
This participation marks an important step for Jumbo Sheen Fund in engaging with the medical innovation ecosystem. Going forward, Jumbo Sheen Fund will maintain close coverage of the innovative drugs and devices space, continue to identify high-growth quality targets, collaborate with ecosystem partners, and facilitate high-quality development of China’s medical innovation industry.
Jumbo Sheen FundDisclaimer:The content involved in this article is for sharing and exchange purposes only, and shall not be construed as investment advice. It is provided merely for readers' reference. All copyrights of the quoted content belong to the original authors. If any infringement is found, please contact us for removal.
